Welcome to Herreros OncoResearch!

I am a researcher specialized in immuno-oncology and the development of preclinical cancer models, with experience in international collaborations in academia and industry. My academic background includes a Bachelor's degree in Biotechnology and a Master's degree in Biomedical Biotechnology, both completed with outstanding marks. Throughout my career, I have worked in laboratories in Spain, the United States, Belgium, and the Netherlands, and I have been awarded 7 competitive predoctoral and postdoctoral fellowships, securing over €850,000 in funding and participating in 15 research projects with a total budget exceeding €2 million.

My achievements include the publication of 25 scientific articles (19 Q1, 5 D1), 10 as the first author and 4 as the corresponding author, in high-impact journals such as Seminars in Cancer Biology and Clinical and Translational Medicine. Additionally, I have contributed to the development of an immuno-carcinogenic assay for breast cancer, currently in its validation stage. I have presented my work at 77 national and international conferences, earning 5 awards, and I have extensive experience as a reviewer for over 15 scientific journals and as a member of editorial boards. 

My teaching experience includes over 200 hours in human physiology, molecular biology of cancer, and immunology at universities in Spain, Belgium, and the United States. I currently supervise two Ph.D. students and several master’s students. Moreover, I have participated in scientific outreach activities and built a robust international collaboration network with basic and translational researchers, enhancing my ability to lead interdisciplinary projects. 

In the medium term, my goal is to establish a research line focused on developing innovative preclinical models to advance personalized immuno-oncology therapies. In the long term, I aim to contribute to understanding the molecular mechanisms driving treatment resistance, facilitating the design of translational therapeutic strategies with direct clinical impact.